Australia markets closed

Instil Bio, Inc. (TIL)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
11.10+0.09 (+0.82%)
At close: 04:00PM EDT
11.01 -0.09 (-0.81%)
After hours: 04:06PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.01
Open11.01
Bid11.00 x 100
Ask11.50 x 900
Day's range10.95 - 11.10
52-week range6.08 - 14.00
Volume8,562
Avg. volume32,121
Market cap72.193M
Beta (5Y monthly)1.26
PE ratio (TTM)N/A
EPS (TTM)-24.00
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est36.00
  • Zacks

    What Makes Instil Bio (TIL) a New Buy Stock

    Instil Bio (TIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

  • GlobeNewswire

    Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

    DALLAS, March 21, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its fourth quarter and full year 2023 financial results and provided a corporate update. Recent Highlights: Announced entering into a strategic collaboration to develop an autologous folate receptor α (FRα)-CoStAR enhanced TIL for a potential investigator-initiated trial (IIT) in non-small cell lung ca

  • Zacks

    Instil (TIL) Stock Rises More Than 20% in a Week: Here's Why

    Instil's (TIL) recent deal with a collaborator to carry out preclinical manufacturing feasibility studies on its ITIL-306 program is a positive.